Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FWS reduces minimum age requirement for ginseng export

This article was originally published in The Tan Sheet

Executive Summary

The US Fish and Wildlife Service (FWS) has restored the five-year age requirement for exported American ginseng, reversing its decision of a year ago to up the requirement to 10 years 1("The Tan Sheet," August 15, 2005, p. 12) The agency says that allowing the plant to be cut at five years "will not be detrimental to the survival of the species." The change comes as a relief to ginseng growers, who last year were disconcerted by the 10-year ruling and complained to the agency. FWA held four public meetings to get feedback from the industry in anticipation of the issuance of FWS 2006 wild American ginseng findings. Meanwhile, FWA is putting together a new outreach tool for ginseng growers and cultivators of medicinal herbs - a web page that will include information about international trade in CITES-listed medicinal plant species...

You may also be interested in...



Ginseng Export Finding May Cause “Significant” Drop In Wild Harvest – AHPA

The U.S. Department of Interior Fish & Wildlife Services' finding on the export of whole wild American ginseng will affect the entire whole-plant ginseng harvest for the next five years, says the American Herbal Products Association

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says

Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel